NCT05043987 is a Phase 1 clinical trial of CPO102 in Pancreatic Cancer, sponsored by Conjupro Biotherapeutics, Inc..

Who is sponsoring NCT05043987?

NCT05043987 is sponsored by Conjupro Biotherapeutics, Inc..

What drugs are being tested in NCT05043987?

Interventions in NCT05043987: CPO102.

What condition does NCT05043987 study?

NCT05043987 studies Pancreatic Cancer, Gastric Cancer.

Is NCT05043987 still recruiting?

NCT05043987 is currently withdrawn. Last updated 7 September 2023.

Last reviewed 2023-09-07 · How we verify

NCT05043987

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers

Withdrawn Phase 1 Last updated 7 September 2023

What this trial tests

Phase 1 trial testing CPO102 in Pancreatic Cancer. Withdrawn.

Timeline

16 November 2022

Primary endpoint
16 November 2022

16 November 2022

Quick facts

Lead sponsor	Conjupro Biotherapeutics, Inc.
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Start date	16 November 2022
Primary completion	16 November 2022
Estimated completion	16 November 2022

Drugs / interventions tested

CPO102 — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →
Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Conjupro Biotherapeutics, Inc. — full company profile →

Who can join

18 and older, any sex, with Pancreatic Cancer or Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 1 study will be a multicenter, single agent, dose escalation and dose expansion study conducted in patients with advanced late stage cancer (pancreatic or gastric including esophageal junction cancers) for which the investigator determines there to be no other standard of care or higher priority therapies available.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
Cao W, Xing H, Li Y, Tian W, et al · · 2022 · cited 127× · PMID 35642043 · DOI 10.1186/s40364-022-00385-1
Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications.
Chen J, Xu Z, Hu C, Zhang S, et al · · 2023 · cited 49× · PMID 36969060 · DOI 10.3389/fonc.2023.1132319
Resistance to antibody-drug conjugates: A review.
Li S, Zhao X, Fu K, Zhu S, et al · · 2025 · cited 32× · PMID 40177568 · DOI 10.1016/j.apsb.2024.12.036
The dawn of precision medicine in diffuse-type gastric cancer.
Ooki A, Yamaguchi K. · · 2022 · cited 31× · PMID 35281349 · DOI 10.1177/17588359221083049
Claudin18.2 in Advanced Gastric Cancer.
Inamoto R, Takahashi N, Yamada Y. · · 2023 · cited 25× · PMID 38136288 · DOI 10.3390/cancers15245742
Antibody drug conjugates: hitting the mark in pancreatic cancer?
Wittwer NL, Brown MP, Liapis V, Staudacher AH. · · 2023 · cited 22× · PMID 37880707 · DOI 10.1186/s13046-023-02868-x
Antibody drug conjugates in the clinic.
Udofa E, Sankholkar D, Mitragotri S, Zhao Z. · · 2024 · cited 12× · PMID 39545074 · DOI 10.1002/btm2.10677
Claudins: from gatekeepers of epithelial integrity to potential targets in hepato-pancreato-biliary cancers.
Jeon H, Sterpi M, Mo C, Bteich F. · · 2024 · cited 7× · PMID 39391254 · DOI 10.3389/fonc.2024.1454882

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Conjupro Biotherapeutics, Inc. trials

Trials by the same sponsor.

NCT04675450 — NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy · Phase 2 · withdrawn
NCT04853329 — Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma · Phase 1 · terminated
NCT03567694 — Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers · Phase 1 · withdrawn
NCT04931823 — Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors · Phase 1 · terminated
NCT03657550 — Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05043987 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Conjupro Biotherapeutics, Inc.
Last refreshed: 7 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05043987.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing